Navigation Links
Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
Date:9/12/2007

Over 20 Targanta-Related Posters and Presentations Accepted to Meeting

CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Targanta Therapeutics Corporation today announced that 23 presentations will showcase its lead antibiotic candidate, oritavancin, and its antibiotic drug discovery platform at the upcoming 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Chicago, September 17-20, 2007.

Thomas Parr, Ph.D., Chief Scientific Officer of Targanta Therapeutics commented on the meeting: "We are very proud of the body of data being presented on behalf of Targanta at ICAAC this year-a true testament, we believe, to the efforts and expertise of our scientists and collaborators. We continue to be encouraged by the breadth of data supporting the differentiating characteristics of oritavancin and are pleased to be able to present for the first time promising data on our pre-clinical osteomyelitis program."

Throughout the meeting, multiple posters will highlight the in vitro activity of oritavancin, Targanta's investigational antibiotic for the treatment of gram-positive infections, against a wide spectrum of antibiotic susceptible and resistant gram-positive bacteria. In addition, two presentations at ICAAC will highlight Targanta's proprietary drug discovery platform, which utilizes bisphosphonate prodrugs of antibiotics to generate molecules that deliver antibiotics directly to the bone.

The following abstracts have been accepted for poster or slide presentation at ICAAC:

Date Time Number Type Author Title

Monday, 12:00- A-49 Poster Lehoux PK-PD of Oritavancin

Sept. 17 1:00PM CDT (ORI) Against

Streptococcus pneumoniae

(SP) in a Murine-Pneumonia

Infection Model

A-50 Poster McKay In vitro Post Antibiotic

Effect Studies of

Oritavancin against

Staphylococcus aureus and

Enterococci

A-51 Poster Bhavnani Use of Pharmacokinetic-

Pharmacodynamic (PK-PD)

Principles to Guide

Clinical Drug Development

for Oritavancin (ORI)

D-241 Poster Tomfohrde Newly Defined In Vitro

Quality Control Ranges for

Oritavancin Broth

Microdilution Testing and

the Effect of Variations

in Testing Conditions on

MIC Results

D-242 Poster Arhin Activity of Oritavancin

against Drug-resistant

Staphylococcus aureus in

the Presence of

Polysorbate-80

Wed., 10:00AM- B-1356 Slide Lehoux In Vivo Efficacy of a New

Sept. 19 10:15AM Osteotropic Prodrug in a

CDT Rabbit Model of Chronic

Osteomyelitis

10:15AM- B-1357 Slide Tanaka Preparation and In vitro

10:30AM Evaluation of

CDT Fluoroquinolone Prodrugs

for the Prevention and

Treatment of Osteomyelitis

Wed., 11:15AM- A-1437 Poster Van Bambeke Comparative Intracellular

Sept. 19 12:15PM Activity of 10

CDT Antistaphylococcal

Antibiotics (AABs) Against

a Stable Small Colony

Variant (SCV) of S. aureus

in a model of human THP-1

macrophages

C1-1471 Poster Arhin Mechanisms of Action of

Oritavancin in

Staphylococcus aureus

C1-1472 Poster Belley Differential Targeting of

Cell Wall Assembly Systems

by Oritavancin

C1-1473 Poster Rafai Far Cell-Wall Binding Sites of

Desleucyl (fluorophenyl)

benzylchloroeremomycin, a

Damaged Oritavancin

Analogue, in

Staphylococcus

aureus

C1-1474 Poster Wang Probing the Mechanism of

Inhibition of Bacterial

Peptidoglycan

Glycosyltransferases by

Glycopeptide Analogs

Wed., 12:15PM- E-1612 Poster Moeck In Vitro Activity Profile

Sept. 19 1:15PM of Oritavancin against a

CDT Broad Spectrum of Aerobic

and Anaerobic Bacterial

Pathogens

E-1613 Poster Grover In Vitro Activity Profile

of Oritavancin (ORI)

against Organisms

Demonstrating Key

Resistance Profiles to

Other Antimicrobial Agents

E-1614 Poster McKay In Vitro Time Kill Studies

of Oritavancin against

Drug-resistant Isolates of

Staphylococcus aureus and

Enterococci

E-1615 Poster Sahm Anti-Enterococcal Activity

Profile or Oritavancin, a

Potent Lipoglycopeptide

under Development for Use

against Gram-Positive

Infections

E-1616 Poster Draghi Anti-Streptococcal

Activity Profile of

Oritavancin, a

Potent Lipoglycopeptide

under Development for Use

against Gram-Positive

Infections

E-1617 Poster Sahm In Vitro Activity Profile

of Oritavancin against

Resistant Staphylococcal

Populations from a Recent

Surveillance Initiative

E-1618 Poster Wilcox In Vitro Susceptibility of

Genotypically Distinct

Clostridium difficile

Strains to Oritavancin

E-1619 Poster Belley Synergistic Effects of

Oritavancin Tested in

Combination with Other

Agents

E-1620 Poster Belley Pharmacokinetic

Concentrations of

Oritavancin Kill

Stationary-Phase and

Biofilm Staphylococcus

aureus in Vitro

E-1621 Poster Arhin Impact of Human Serum

Albumin on Oritavancin In

vitro Activity against

Staphylococcus aureus

E-1627a Poster Baines Activity of

Metronidazole,

Vancomycin and

Oritavancin

against Epidemic

Clostridium difficile

spores

About Oritavancin

Oritavancin is a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal (killing) activity against a broad spectrum of gram-positive bacteria. The product candidate has been tested in over 1500 patients and has completed two Phase 3 studies for the treatment of complicated skin and skin structure infection (cSSSI) in which the primary endpoints were met. Targanta believes oritavancin's properties may give it distinct advantages over currently marketed therapies and expects to submit a New Drug Application to the U.S. Food and Drug Administration in the first quarter of 2008 seeking to commercialize oritavancin for the treatment of cSSSI.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a privately held biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, Montreal, Quebec, Canada and Toronto, Ontario, Canada. For further information about Targanta, visit the company's website at http://www.targanta.com.

Disclaimer

All forward-looking statements and other information included in this press release are based on information available to Targanta as of the date hereof, and Targanta assumes no obligation to update any such forward-looking statements or information. Targanta's actual results could differ materially from those described in Targanta's forward-looking statements.


'/>"/>
SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Emerging technology companies receive significant funding
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. BIO 2007: Wisconsin makes its presence felt
5. TDS trades markets to gain Duluth presence
6. West Coast VC Establishes Midwest Presence in Madison
7. Sony Bets Heavy on Wisconsin Digital Entertainment Presence
8. NameProtect releases annual list of top trademarkers
9. Doyle says new contracts saving state more than $16 million annually
10. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
11. Annual Bioethics Forum to explore genetic testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
(Date:6/22/2016)... 2016  According to Kalorama Information, the dominant ... market include significant efforts in automation as well ... and affordable sequencers, say the healthcare market research ... including sample prep materials.  The healthcare market research ... for Next Generation Sequencing (NGS) , highlights major ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):